5:09 PM
 | 
May 07, 2019
 |  BC Extra  |  Company News

Regeneron falls after reporting EPS below the Street and disclosing patient deaths

Regeneron lost $2.4 billion in market cap Tuesday after reporting 1Q19 EPS well below consensus and disclosing two patient deaths in a Phase I trial evaluating its bispecific mAb targeting CD20 and CD3, REGN1979, in combination with anti-PD-1 mAb Libtayo cemiplimab-rwlc.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) President and CSO George Yancopoulos said on the company's earnings call Tuesday that the bispecific and PD-1 inhibitor combo led to "enhanced" cytokine release syndrome (CRS) associated with increased toxicities in patients with advanced lymphoma, including two potentially related fatalities potentially related to CRS.

"Heightening the immune response via combination approaches carries inherent risks, as occurs...

Read the full 482 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >